Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Deals

Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership

Fineline Cube Feb 3, 2026

Zonsen Peplib Biotech Inc., a China‑based polypeptide lead compound developer, announced a collaboration with Eli...

Company Drug

Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis

Fineline Cube Feb 3, 2026

Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for...

Company Deals

WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases

Fineline Cube Feb 3, 2026

WuXi Biologics (HKG: 2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T‑cell engager...

Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026

The National Medical Products Administration (NMPA) released the 101st batch of reference drugs for generic...

Company Deals

Zenshine Pharma Files for Hong Kong IPO with $357M Valuation

Fineline Cube Feb 2, 2026

Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main...

Company Deals

Moderna Partners with Recordati on mRNA-3927 for Rare Propionic Acidemia

Fineline Cube Feb 2, 2026

Moderna Inc. (NASDAQ: MRNA) announced a global partnership with Italy‑based Recordati for mRNA-3927, an investigational mRNA...

Company Deals

Illumina Completes $350M SomaLogic Acquisition to Expand Proteomics Portfolio

Fineline Cube Feb 2, 2026

Illumina (NASDAQ: ILMN) announced the completion of its acquisition of SomaLogic, a leader in data‑driven proteomics...

Company Medical Device

Microport EP Medtech’s EasyEcho ICE Catheter Wins NMPA Market Clearance

Fineline Cube Feb 2, 2026

Shanghai Microport EP Medtech Co., Ltd. (SHA: 688351) announced that the National Medical Products Administration...

Policy / Regulatory

NHSA Targets NRDL Fund Supervision in 2026 Crackdown

Fineline Cube Feb 2, 2026

China’s National Healthcare Security Administration (NHSA) this week issued the “Notice on Further Enhancing the...

Company

Regeneron Q4 Revenue Grows 3% to $3.9B on EYLEA HD and Dupixent Strength

Fineline Cube Feb 2, 2026

Regeneron Pharmaceuticals (NASDAQ: REGN) reported fourth‑quarter 2025 revenues of $3.884 billion , up 3% year‑on‑year (YOY), bringing...

Company Deals

Vcare Pharma Partners with Sun-Novo on VC005 JAK1 Inhibitor for Atopic Dermatitis

Fineline Cube Feb 2, 2026

Jiangsu Vcare PharmaTech Co., Ltd. announced a partnership with Beijing Sun-Novo Pharmaceutical Research Co., Ltd....

Company Drug

Sciwind’s Ecnoglutide Wins NMPA Nod as First cAMP‑Biased GLP‑1 Agonist

Fineline Cube Feb 2, 2026

Sciwind Biosciences Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved ecnoglutide...

Policy / Regulatory

FDA Opens PreCheck Applications to Strengthen Domestic Drug Manufacturing

Fineline Cube Feb 2, 2026

The U.S. Food and Drug Administration this week began accepting applications for the FDA PreCheck...

Company Drug

Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages

Fineline Cube Feb 2, 2026

Ab&b Bio-Tech Co.,Ltd. (HKG: 2627) announced that the National Medical Products Administration (NMPA) has granted...

Company Drug

Sanofi Rezurock Wins EU Backing for Graft‑Versus‑Host Disease

Fineline Cube Feb 2, 2026

Sanofi (NASDAQ: SNY) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human...

Company Drug

CMS-D017 Gets NMPA Nod for PNH Clinical Trial

Fineline Cube Feb 2, 2026

China Medical System Holdings (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has...

Company Drug

J&J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer

Fineline Cube Feb 2, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products for Human Use...

Company Drug

Hengrui Ruitanning Gets NMPA Nod for Moderately Emetogenic Chemo Indication

Fineline Cube Feb 2, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)...

Company Drug Policy / Regulatory

CDE Seeks Feedback on 103rd Batch of Generic Reference Preparations

Fineline Cube Feb 2, 2026

The Center for Drug Evaluation (CDE) is seeking industry feedback on the 103rd batch of...

Company Deals

Kyowa Kirin Reclaims Rocatinlimab Rights from Amgen in Strategic Shift

Fineline Cube Feb 2, 2026

Kyowa Kirin (TYO: 4151) announced it will cancel its licensing agreement with Amgen (NASDAQ: AMGN) for...

Posts pagination

1 … 78 79 80 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.